[Relationship between expression of @entity5689 and pERK1/2 and prognosis in XXXX ].

@entity1 @entity5 @entity1149 @entity5689 @entity7952 @entity3 @entity3895
OBJECTIVE: To study the relationship between expression of @entity5689 ( @entity3895 -1) and pERK1/2 and prognosis in @entity1149 ( @entity1149 ). METHODS: @entity3895 -1 and pERK1/2 protein expression was assessed by immunohistochemistry in samples obtained from 160 @entity1 with @entity1149 and 20 @entity1 with normal lung tissue. RESULTS: Normal bronchial and alveolar epithelial cells were positive for @entity3895 -1 (membranous and cytoplasmic staining patterns). The expression rate of @entity3895 -1 in @entity1149 was 65.6% (105/160), which was significantly lower than that in normal lung tissue (P = 0.002). The @entity3895 -1-positive rates in well to moderately differentiated @entity5 and poorly differentiated @entity5 were 56.8% (46/81) and 75.7% (53/70), respectively (P = 0.015). The expression of @entity3895 -1 was much higher in @entity1 with lymph node @entity3 (77.8%, compared with 55.7% in lymph node-negative group, P = 0.003). The expression was also higher in stage III to IV than in stage I to II disease (75.4%, compared with 58.2%, P = 0.024). The overall survival of @entity1 with @entity3895 -1-positive @entity5 (71.4%, 37.1% and 17.1% 1-, 3- and 5-year survival, respectively) was lower than those with @entity3895 -1-negative @entity5 (89.1%, 69.1% and 43.6% 1-, 3- and 5-year survival, respectively, P = 0.000). On the other hand, normal bronchial and alveolar epithelial cells were negative for pERK1/2. The expression rate of pERK1/2 in @entity1149 was 61.3%, which was significantly higher than that in normal lung tissues (P = 0.000). The pERK1/2-positive rates in well to moderately differentiated @entity5 and poorly differentiated @entity5 was 53.1% and 71.4%, respectively (P = 0.021). The expression of pERK1/2 was much higher in @entity1 with lymph node @entity3 (80.6%, compared with 45.5% in lymph node-negative group, P = 0.000). The expression of pERK1/2 was also higher in stage III to IV than in stage I to II disease (76.8%, compared with 49.5%, P = 0.426). The overall survival of @entity1 with @entity7952 1/2-positive @entity5 (74.5%, 42.9% and 19.4% 1-, 3- and 5-year survival, respectively) was lower than those with pERK1/2-negative @entity5 (82.3%, 56.5% and 37.1% 1-, 3- and 5-year survival, respectively, P = 0.002). @entity3895 -1 and pERK1/2 expression showed negative correlation (P = 0.000). CONCLUSIONS: @entity3895 -1 expression is lower in @entity1149 than in normal lung tissue, whereas pERK1/2 expression is higher in @entity1149 . Positive expression of @entity3895 -1 and overexpression of pERK1/2 correlates with tumorigenesis and @entity5 progression of @entity1149 . @entity3895 -1 and pERK1/2 may serve as potential markers for predicting prognosis in @entity1149 .
